Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs
30 janv. 2024 07h00 HE
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio,...
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
25 janv. 2024 14h29 HE
|
Regeneron Pharmaceuticals, Inc.
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo Expanded indication marks second disease for...
Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards
24 janv. 2024 12h00 HE
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y. and WASHINGTON, D.C., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in...
Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement
16 janv. 2024 07h00 HE
|
Regeneron Pharmaceuticals, Inc.
Data included from first and only Phase 3 trial specifically evaluating a biologic in this difficult-to-treat population Phase 3 trial showed more than twice as many patients treated with Dupixent...
Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024
05 janv. 2024 16h05 HE
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2023 financial and operating...
Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
18 déc. 2023 16h05 HE
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday,...
Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year
11 déc. 2023 07h30 HE
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its inclusion on the Dow Jones Sustainability World Index (DJSI World) for the fifth...
Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes
10 déc. 2023 19h30 HE
|
Regeneron Pharmaceuticals, Inc.
Updated results presented at ASH demonstrated an 80% objective response rate and a 73% complete response (CR), with a 23-month median duration of response and 24-month median duration of CR Oral...
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
10 déc. 2023 12h30 HE
|
Regeneron Pharmaceuticals, Inc.
Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate (ORR), with 31% achieving a complete response (CR) Results from a Phase 1 expansion cohort...
Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma
07 déc. 2023 07h00 HE
|
Regeneron Pharmaceuticals, Inc.
71% objective response rate, with 46% achieving a complete response or better after 11 months of median follow-up Data to be submitted to regulatory authorities, with Biologics License...